Status:
COMPLETED
Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function
Lead Sponsor:
Sanofi
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE4
Brief Summary
To determine whether in the laser Doppler flowmetric parameters characteristic of endothelial dysfunction at patients with clinically manifest atherosclerosis any change can be detected at plavix (clo...
Eligibility Criteria
Inclusion
- Proven, peripheral arterial disease, Fontain II-III stage, patient submitted to secondary prophylactic thrombocyte aggregation inhibiting treatment
- Doppler index \< 0,8
Exclusion
- Hypersensitivity to the active ingredient or one of the components of the drug
- Active pathological bleeding, e.g. gastric ulcer, intracranial bleeding
- Pregnancy, breast-feeding
- Severe, known hepatic insufficiency
- Severe, known renal insufficiency
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00648453
Start Date
December 1 2002
End Date
April 1 2004
Last Update
April 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Budapest, Hungary